The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice
Canadian Respiratory Journal · 2024
DOI: 10.1155/carj/8827810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2024. Verfasst von Jianfeng Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Lung Neoplasms, ErbB Receptors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Provincial Administration of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
This study aimed to investigate the effect of Fuzheng Yiai Decoction (FZYA) on epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) drug resistance in lung adenosquamous carcinoma (ASC). The expression of thyroid transcription factor 1 (TTF1) and p63 in tumor cells was observed by immunofluorescence staining. Meanwhile, 25 nude mice successfully inoculated with the human lung ASC cell line NCI‐H596 were randomly divided into five groups, namely, the model, gefitinib, low‐, medium‐, and high‐dose FZYA with gefitinib groups. After four weeks of daily intragastric administration of the various treatments, the tumor weight and volume inhibition rates were calculated. The positive expression rate and protein expression of TTF1 and p63 in mouse tumor tissues were evaluated by immunohistochemistry and western blot assays. The results showed that the adenocarcinoma part and the squamous cell carcinoma part of the lung tissue were not either one or the other, and each had unique biological behavior patterns. In terms of the tumor volume and weight, gefitinib treatment along with FZYA reduced the acquired resistance of EGFR‐TKIs in lung ASC, and its inhibitory effect was superior to EGFR‐TKI (gefitinib) treatment alone. Moreover, it was discovered that FZYA inhibited the pedigree transformation among cancer subtypes due to EGFR‐TKI treatment. In conclusion, the application of FZYA inhibited the pedigree transformation among lung cancer subtypes, thus increasing the tumor inhibitory effect and decreasing the EGFR‐TKI drug resistance of tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
- Sichuan Acupuncture and Moxibustion School, Chengdu 610097, China.
ORCID-Profile: Jianfeng Sun, Danqing Luo, Hui Li, Di Zhang, Yesha Liu, Song Jin, Hong Guo, Chengshi He, Zhipeng Wu
Förderung
- Sichuan Provincial Administration of Traditional Chinese Medicine
- Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Sun, J., Luo, D., Li, H., Zhang, D., Liu, Y., Jin, S., Guo, H., He, C., & Wu, Z. (2024). The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice. Canadian Respiratory Journal. https://doi.org/10.1155/carj/8827810
Vancouver
Sun J, Luo D, Li H, Zhang D, Liu Y, Jin S, et al. The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice. Canadian Respiratory Journal. 2024. doi:10.1155/carj/8827810
BibTeX
@article{Sun2024,
author = {Sun, Jianfeng and Luo, Danqing and Li, Hui and Zhang, Di and Liu, Yesha and Jin, Song and Guo, Hong and He, Chengshi and Wu, Zhipeng},
title = {The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice},
journal = {Canadian Respiratory Journal},
year = {2024},
doi = {10.1155/carj/8827810}
}
EUVIMED